Concepedia

Author

Javier Castañeda

Medtronic (Switzerland)ORCID

Also Known As

Castaneda, Javier, H. Gough, J Castaneda, J Castañeda, J. A. Castañeda, J. Castaneda, J. Castañeda, J., Castañeda, J.A. Carmona Castañeda, J.A. Galindo Castaneda

102

Publications

2.4K

Citations

24

H-Index

41

Concepts

All Affiliations

Medtronic (Switzerland)Medtronic (Netherlands)Medtronic (United States)Universidad de ValladolidSheba Medical Center
JC

About

Javier Castañeda is an author at Medtronic (Switzerland) specializing in medicine, physiology, and diabetes.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

716

2

Diabetes

4

4

550

3

Health Sciences

1

1

22

4

Social Sciences

1

1

51

5

Biomedical Engineering

1

1

22

Javier Castañeda

×

33

Publications

2K

Citations

23

H-Index

YearCitations

Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial

Yves Reznik, Ohad Cohen, Ronnie Aronson,

The Lancet

2014

228

Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users

Julien Da Silva, Giuseppe Lepore, Tadej Battelino,

Diabetes Technology & Therapeutics

2021

207

Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study

Pratik Choudhary, Ralf Kolassa, Winfried Keuthage,

The Lancet Diabetes & Endocrinology

2022

179

Comparison of <scp>MiniMed 780G</scp> system performance in users aged younger and older than 15 years: Evidence from 12 870 real‐world users

Arcelia Arrieta, Tadej Battelino, Andrea Scaramuzza,

Diabetes Obesity and Metabolism

2022

145

Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial

Emanuele Bosi, Pratik Choudhary, Harold W. de Valk,

The Lancet Diabetes & Endocrinology

2019

121

Activation of neutral sphingomyelinase is involved in acute hypoxic pulmonary vasoconstriction

Ángel Cogolludo, Laura Moreno, Giovanna Frazziano,

Cardiovascular Research

2008

112

Routine Sensor-Augmented Pump Therapy in Type 1 Diabetes: The INTERPRET Study

Kirsten Nørgaard, Andrea E. Scaramuzza, Nataša Bratina,

Diabetes Technology & Therapeutics

2013

107

Predictors of time in target glucose range in real‐world users of the <scp>MiniMed 780G</scp> system

Javier Castañeda, Chantal Mathieu, Henk‐Jan Aanstoot,

Diabetes Obesity and Metabolism

2022

94

Time in Tight Glucose Range in Type 1 Diabetes: Predictive Factors and Achievable Targets in Real-World Users of the MiniMed 780G System

Javier Castañeda, Arcelia Arrieta, Tim van den Heuvel,

Diabetes Care

2023

80

Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12‐month data from the <scp>OpT2mise</scp> randomized trial

Ronnie Aronson, Yves Reznik, Ignacio Conget,

Diabetes Obesity and Metabolism

2016

64

Page 1